➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Dow
McKesson
Express Scripts
Harvard Business School

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PURINETHOL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Purinethol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00287170 Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease Completed Teva GTC Phase 1/Phase 2 2006-07-01 The study is being undertaken to evaluate whether delayed-release medications, designed to begin to open in the lower intestinal tract, the main site of Crohn's Disease, are more effective than standard systemically delivered drugs to promote remission or response in CD patients. It is hypothesized that the delayed-release medications will go right to the injured tissue and heal the disease more quickly. The delayed-release test drugs are 6-mercaptopurine (at a dose of 40 mg daily) or calcitriol (at a dose of 5 mcg three times a week) versus Purinethol (6-MP at a dose of 1-2 mg/kg body weight daily). Calcitriol is a synthetically manufactured replica of a natural substance in the body that is derived from Vitamin D. There is much medical evidence that shows that lack of Vitamin D can be a possible risk factor in developing autoimmune disorders, including Crohn's Disease. Moreover, calcitriol has been shown in animal models to improve the symptoms of Crohn's Disease.
NCT00548431 NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia Completed Rigshospitalet, Denmark Phase 2 2007-12-01 The present pharmacokinetic (PK)-pharmacodynamic (PD) study will explore the toxicity and antileukemic response during the initial 3 months of individualised therapy of children and young adults with acute lymphoblastic leukemia (ALL). The investigators will on an individual toxicity-titrated basis attempt to increase the dose intensity of the 6-mercaptopurine used in the two-months post-remission treatment phase of lower risk childhood ALL. This will be performed together with continuous PEG-ASP (every 2nd week) and interspersed HD-MTX (5 g/m^2) every 3rd week. Thus, the trial will also test the feasibility of this particular drug combination.
NCT00602134 Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions Completed Roxane Laboratories N/A 2002-11-01 The objective of this study was to assess the bioequivalence of a potential generic 6-mercaptopurine 50 mg tablet formulation compared with GlaxoSmithKline Purinethol® (mercaptopurine) 50-mg scored tablets following a single 50 mg oral dose administered in the fasted state.
NCT00648336 Fasting Study of Mercaptopurine 50 mg and Purinethol® Tablets 50 mg Completed Mylan Pharmaceuticals Phase 1 2003-11-01 The objective of this study was to investigate the bioequivalence of Mylan's mercaptopurine 50 mg tablets to Gate's Purinethol® 50 mg tablets following a single, oral 50 mg (1 x 50 mg) dose administered under fasting conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Purinethol

Condition Name

Condition Name for Purinethol
Intervention Trials
Acute Lymphoblastic Leukemia 6
Crohn's Disease 3
Leukemia 3
B Acute Lymphoblastic Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Purinethol
Intervention Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 15
Leukemia, Lymphoid 14
Leukemia 13
Crohn Disease 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Purinethol

Trials by Country

Trials by Country for Purinethol
Location Trials
United States 55
Israel 4
Denmark 2
Netherlands 1
Sweden 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Purinethol
Location Trials
Texas 6
Arizona 2
Pennsylvania 2
North Dakota 2
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Purinethol

Clinical Trial Phase

Clinical Trial Phase for Purinethol
Clinical Trial Phase Trials
Phase 4 2
Phase 3 5
Phase 2 9
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Purinethol
Clinical Trial Phase Trials
Completed 6
Not yet recruiting 6
Recruiting 6
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Purinethol

Sponsor Name

Sponsor Name for Purinethol
Sponsor Trials
National Cancer Institute (NCI) 6
M.D. Anderson Cancer Center 5
Teva GTC 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Purinethol
Sponsor Trials
Other 16
Industry 12
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
McKinsey
Dow
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.